ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO

ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO

Business Wire

Published

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Final Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin® at ESMO

Full Article